Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/rccm.201001-0123OCPMID 20581169PMCID PMC3001259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

  2010cited by this paper
• Long Term Use Of Imatinib In Patients With Severe Pulmonary Arterial Hypertension

  2010cited by this paper
• IMATINIB MESYLATE TREATMENT FOR SEVERE PULMONARY ARTERIAL HYPERTENSION: A PROPOSED PHASE III 24-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL

  2009cited by this paper
• Diagnosis and assessment of pulmonary arterial hypertension.

  2009cited by this paper
• Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

  2009cited by this paper
• Cellular and molecular basis of pulmonary arterial hypertension.

  2009cited by this paper
• Tadalafil Therapy for Pulmonary Arterial Hypertension

  2009cited by this paper
• Imatinib in Patients with Severe Pulmonary Artery Hypertension (PAH) Refractory to Standard Therapy.

  2009cited by this paper
• Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.

  2008cited by this paper
• Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension

  2008cited by this paper
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

  2008cited by this paper
• A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

  2008cited by this paper
• In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

  2007cited by this paper
• A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology.

  2007cited by this paper
• Flying under the radar: the new wave of BCR–ABL inhibitors

  2007cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• Reduced exercise capacity in a mouse model of asthma

  2006cited by this paper
• Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.

  2006cited by this paper
• Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

  2006cited by this paper
• Long term imatinib treatment in pulmonary arterial hypertension.

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Imatinib for the treatment of pulmonary arterial hypertension.

  2005cited by this paper
• Sildenafil citrate therapy for pulmonary arterial hypertension.

  2005cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• Alterations in Ca2+ cycling by lysoplasmenylcholine in adult rabbit ventricular myocytes.

  2003cited by this paper
• Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus.

  2003cited by this paper
• Mild hypoxia impairs alveolarization in the endothelial nitric oxide synthase-deficient mouse.

  2003cited by this paper
• ATS statement: guidelines for the six-minute walk test.

  2002cited by this paper
• Bosentan therapy for pulmonary arterial hypertension.

  2002cited by this paper
• Mechanism of action and in vivo role of platelet-derived growth factor.

  1999cited by this paper
• Superoxide anion production by monocytes of corticosteroid-treated asthmatic patients.

  1998cited by this paper
• Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients.

  1998cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996cited by this paper
• Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

  1991cited by this paper

• Recent Advances in Targeted Therapy for Connective Tissue Disease-associated Pulmonary Arterial Hypertension

  2026cites this paper
• Cross-pollination of two specialties: potential repurposing of cancer and cardiovascular drugs for the benefit of the other.

  2025cites this paper
• Specialized pericyte subtypes in the pulmonary capillaries

  2025cites this paper
• Anti-remodeling therapies in pulmonary arterial hypertension.

  2025cites this paper
• Another Act in the Story of Oral Imatinib for Pulmonary Arterial Hypertension

  2025cites this paper
• Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling

  2025cites this paper
• Drugs and toxins associated with pulmonary arterial hypertension: from established culprits to novel threats

  2025cites this paper
• Important negative trials in pulmonary hypertension.

  2025cites this paper
• Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials: a systematic review, meta-analysis and health-related quality of life framework

  2025cites this paper
• Targeting PDGFR, EGFR, FGFR, and VEGFR: Key Receptor Tyrosine Kinases‐Driven Metabolic Reprogramming in Pulmonary Arterial Hypertension

  2025cites this paper
• Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study

  2025cites this paper
• Efficacy and Safety of Treating Pulmonary Arterial Hypertension With Imatinib: A Meta-Analysis of Randomized Controlled Trials

  2025influential citation
• Imatinib aggravates pressure‐overload‐induced right ventricle failure via JNK/Runx2 pathway

  2025cites this paper
• Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series)

  2025cites this paper
• Tyrosine Kinase Inhibitors for Treatment of Pulmonary Arterial Hypertension

  2025cites this paper
• Drugs targeting novel pathways in pulmonary arterial hypertension

  2025cites this paper
• Unveiling the metabolic landscape of pulmonary hypertension: insights from metabolomics

  2024cites this paper
• Viewing Pulmonary Arterial Hypertension Pathogenesis and Opportunities for Disease-Modifying Therapy Through the Lens of Biomass

  2024cites this paper
• IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension

  2024cites this paper
• Mechanisms and treatment of pulmonary arterial hypertension

  2024cites this paper
• Platelet-derived Growth Factor Receptor-α Induces Contraction Knots and Inflammatory Pain–like Behavior in a Rat Model of Myofascial Trigger Points

  2024cites this paper
• Genetics and precision genomics approaches to pulmonary hypertension

  2024cites this paper
• Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study

  2024cites this paper
• Health-related quality of life in pulmonary arterial hypertension trials: a review and conceptual map

  2024cites this paper
• Panorama of artery endothelial cell dysfunction in pulmonary arterial hypertension.

  2024cites this paper
• Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. From In vitro to In vivo

  2024cites this paper
• Prognostic biomarkers and clinical parameters in adults with atrial septal defect-related pulmonary arterial hypertension treated with sildenafil and beraprost combination therapy

  2024cites this paper
• Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.

  2024cites this paper
• Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

  2024cites this paper
• Constructing the Framework for Disease Modification in Pulmonary Arterial Hypertension.

  2024cites this paper
• Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension—A Systematic Review

  2024cites this paper
• New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review

  2024cites this paper
• Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats

  2024cites this paper
• Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension

  2023cites this paper
• Treatment of pulmonary arterial hypertension: recent progress and a look to the future.

  2023cites this paper
• The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges

  2023cites this paper
• Nouvelles cibles thérapeutiques dans l’HTAP

  2023cites this paper
• Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment.

  2023cites this paper
• Design and Synthesis of Inhibitors of the E3 Ligase SMAD Specific E3 Ubiquitin Protein Ligase 1 as a Treatment for Lung Remodeling in Pulmonary Arterial Hypertension.

  2023cites this paper
• Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?

  2023cites this paper
• The Future of PAH Treatment

  2023cites this paper
• Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management.

  2023cites this paper
• Pulmonary vascular fibrosis in pulmonary hypertension - The role of the extracellular matrix as a therapeutic target.

  2023cites this paper
• Mendelian randomization study on causal association of IL-6 signaling with pulmonary arterial hypertension

  2023cites this paper
• Novel and emerging therapies in pulmonary arterial hypertension

  2022cites this paper
• AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study

  2022cites this paper
• Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages

  2022cites this paper
• Comprehensive Review on Novel Targets and Emerging Therapeutic Modalities for Pulmonary Arterial Hypertension.

  2022cites this paper
• NEW OPPORTUNITIES PATHOGENETIC THERAPY OF PULMONARY ARTERIAL HYPERTENSION

  2022cites this paper
• Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension

  2022cites this paper
• Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis

  2022cites this paper
• Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling

  2022cites this paper
• Early View

  2022cites this paper
• The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.

  2022cites this paper
• Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis

  2022cites this paper
• Management of Pulmonary Hypertension in the Pediatric Patient.

  2022cites this paper
• Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances.

  2021cites this paper
• The Third Man: DNA sensing as espionage in pulmonary vascular health and disease

  2021cites this paper
• mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target

  2021cites this paper
• Endothelin receptor antagonists for pulmonary arterial hypertension.

  2021cites this paper
• Recent advances in pharmacotherapy of pulmonary hypertension: practical considerations.

  2021cites this paper
• Centrality analysis in a drug network and its application to drug repositioning

  2021cites this paper
• iPSC–endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension

  2021cites this paper
• Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension

  2021cites this paper
• Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group

  2021cites this paper
• Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity

  2021cites this paper
• Combination Therapy With Rapamycin and Low Dose Imatinib in Pulmonary Hypertension

  2021cites this paper
• Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy

  2021cites this paper
• Disrupted PI3K subunit p110α signaling protects against pulmonary hypertension and reverses established disease in rodents.

  2021cites this paper
• Phosphoproteomic analysis of lung tissue from patients with pulmonary arterial hypertension

  2021cites this paper
• Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension

  2021cites this paper
• Cardiovascular complications in patients with interstitial lung disease and their correlation with 6-minute walk test and spirometry: A single-center study

  2021cites this paper
• Novel Pharmacological Targets for Pulmonary Arterial Hypertension.

  2021cites this paper
• TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension

  2021cites this paper
• Cancer and pulmonary hypertension: Learning lessons and real-life interplay

  2020cites this paper
• Heart rate monitoring improves clinical assessment during 6-min walk

  2020cites this paper
• EMERGING ANTENATAL THERAPIES FOR CONGENITAL DIAPHRAGMATIC HERNIA-INDUCED PULMONARY HYPERTENSION IN PRECLINICAL MODELS

  2020cites this paper
• Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFR b

  2020cites this paper
• Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension.

  2020cites this paper
• PDGF/MEK/ERK Axis represses Ca2+ clearance via Decreasing the Abundance of Plasma Membrane Ca2+ Pump PMCA4 in Pulmonary Arterial Smooth Muscle Cells.

  2020cites this paper
• Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFRβ

  2020cites this paper
• Limitations and Flaws of Preclinical Pulmonary Hypertension Studies

  2020cites this paper
• Stem/Progenitor Cells and Pulmonary Arterial Hypertension.

  2020cites this paper
• Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors

  2020cites this paper
• 3D in vitro Model of Vascular Medial Thickening in Pulmonary Arterial Hypertension

  2020cites this paper
• Pulmonary capillary haemangiomatosis: a distinct entity?

  2020cites this paper
• Pulmonary arterial hypertension specific therapy: The old and the new.

  2020cites this paper
• Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update.

  2020cites this paper
• ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs

  2020cites this paper
• Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature

  2020cites this paper
• Themed Issue: Pulmonary hypertension and right heart failure: new therapeutic avenue/approaches The application of ‘ omics ’ to pulmonary arterial hypertension

  2020cites this paper
• Current and future treatments of pulmonary arterial hypertension

  2020cites this paper
• Emerging therapies for right ventricular dysfunction and failure.

  2020cites this paper
• IL-6 in pulmonary hypertension: why novel is not always best

  2020cites this paper
• Drug Induced Pulmonary Arterial Hypertension

  2019cites this paper
• Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction

  2019cites this paper
• Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial

  2019cites this paper
• Cardio-oncology: Network-Based Prediction of Cancer Therapy-Induced Cardiotoxicity

  2019cites this paper
• Angiogenesis in Pulmonary Arterial Hypertension-Imaging of the Right Heart in a New Mouse Model

  2019cites this paper
• Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension

  2019cites this paper